Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16958008 | 0.88 | XDH (0.46) | XDHS1PR1KDM4EUSP2ALDH1A1 | |
| SCHEMBL6112880 | 0.88 | XDH (0.46) | XDHS1PR1KDM4EUSP2ALDH1A1 | |
| SCHEMBL16954817 | 0.88 | XDH (0.40) | XDHS1PR1 | |
| SCHEMBL6113065 | 0.82 | S1PR1 (0.47) | XDHS1PR1 | |
| SCHEMBL9034199 | 0.81 | XDH (0.49) | XDHKDM4EUSP2ALDH1A1 | |
| SCHEMBL13193178 | 0.81 | XDH (0.49) | XDHS1PR1KDM4EUSP2ALDH1A1 | |
| SCHEMBL10088433 | 0.81 | AR (0.44) | XDHALDH1A1 | |
| SCHEMBL6113250 | 0.80 | S1PR1 (0.56) | XDHS1PR1 | |
| SCHEMBL22272207 | 0.80 | XDH (0.48) | XDHKDM4EUSP2ALDH1A1 | |
| SCHEMBL1293570 | 0.80 | XDH (0.48) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3492465-B1 | S1P1 AGONIST AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-03-24 | — | — | EP | disclosed |
| CN-107674040-B | Method for converting febuxostat impurities into febuxostat | 天津力生制药股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110156698-A | The preparation method and purposes of 2- phenyl -1,6- dihydro-pyrimidin -5- formic acid derivates | 沈阳海诺威医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-3492465-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | S1PR1, S1PR2, S1PR3 | XDH 3628/4885S1PR1 1/4885KDM4E 3986/4885 |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | S1PR1, S1PR2, S1PR3 | XDH 3628/4885S1PR1 1/4885KDM4E 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.